HHS Announces Over $500M in Project NextGen Awards to Support Vaccine, Tech Development Work
The Department of Health and Human Services has announced more than $500 million in awards to support companies as they move their vaccine candidates to Phase 2b clinical trials and further develop new technologies as part of Project NextGen.
Project NextGen is a $5 billion government initiative that seeks to speed up the development of next-generation vaccines and other treatments through public-private partnerships.
HHS said Friday CastleVax, Codagenix and Gritstone Bio will receive $28 million in awards to continue work on their vaccines.
CastleVax is developing a vector-based intranasal vaccine candidate, while Codagenix is working on a live-attenuated intranasal vaccine. Gritsone Bio’s candidate is a self-amplifying mRNA vaccine.
Read the full article here.